The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients

Arms (2)

1. type

   EXPERIMENTAL

   label

   Intervention group patients will receive anticoagulation management via MTM model

   interventionNames

   1. Behavioral: Medication Therapy Management (MTM) model

2. type

   NO_INTERVENTION

   label

   Control group patients will be managed using a standard care.

Primary outcomes (1)

1. measure

   Clinically Important Medication Errors (CIME) related to anticoagulant therapy

   timeFrame

   From the time of the patient's admission to 6 months after discharge.

   description

   The primary outcome is CIME related to anticoagulation therapy, which constitute a composite endpoint comprising preventable or ameliorable adverse drug events (ADEs) and potential ADEs arising from medication discrepancies or non-adherence. The primary anticoagulant-related ADEs that this trial plans to observe encompass two categories: (i) ADEs associated with the therapeutic effects of anticoagulant, including all-cause mortality, suspected recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), confirmed symptomatic or incidental DVT, and confirmed symptomatic or incidental PE; (ii) ADEs related to the major adverse drug reactions, such as major bleeding, clinical related non-major bleeding, and minor bleeding.